Aptose Biosciences Inc (TSE:APS)‘s stock had its “outperform” rating reissued by Royal Bank Of Canada in a research note issued on Friday. They currently have a C$24.00 price objective on the stock.

Shares of Aptose Biosciences (TSE:APS) opened at 2.85 on Friday. The company’s market cap is $36.74 million. Aptose Biosciences has a 52-week low of $2.51 and a 52-week high of $8.33. The stock has a 50 day moving average of $2.91 and a 200 day moving average of $3.19.

Aptose Biosciences Company Profile

Aptose Biosciences Inc (Aptose) is a clinical-stage biotechnology company. The Company is engaged in the development of anticancer drugs that target specific epigenetic processes and signal transduction abnormalities that underlie a particular life-threatening malignancy. Its product pipeline includes cancer drug candidates that exert activity as stand-alone agents and that enhance the activities of other anticancer agents without causing overlapping toxicities.

Receive News & Stock Ratings for Aptose Biosciences Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aptose Biosciences Inc and related stocks with our FREE daily email newsletter.